Drug intelligence / Profile preview

omega-3 fatty acid ethyl esters

Development stage
Unknown
Lead developer
By-Health
Modality
Small Molecules
Administration
Oral
01

Overview

**Lilexin** is the Chinese prescription brand of omega-3 fatty acid ethyl esters 90 soft capsules developed by Gowell for treatment of hypertriglyceridemia. It is an oral, highly concentrated mixture of omega-3 fatty-acid ethyl esters, principally eicosapentaenoic acid and docosahexaenoic acid ethyl esters. The product lowers triglycerides primarily by reducing hepatic very-low-density-lipoprotein synthesis and secretion while promoting triglyceride breakdown in very-low-density lipoproteins and chylomicrons. Gowell states that Lilexin was approved in China for lowering triglycerides in adults with severe hypertriglyceridemia. ([cdgowell.com](https://www.cdgowell.com/newsinfo.aspx?ContentID=1287&Type=12))

Brand names
Lilexin立乐欣
Other names
omega-3-acid ethyl estersomega3-acid ethyl estersomega 3-acid ethyl estersomega-3 fatty acid ethyl ester 90omega3 fatty acid ethyl ester 90omega 3 fatty acid ethyl ester 90ω-3脂肪酸乙酯90软胶囊
02

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)FFAR4 (Free fatty acid receptor 4)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on omega-3 fatty acid ethyl esters.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omega-3 fatty acid ethyl esters.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call